ERBB2 and breast cancer: Patients were stratified into training and validation cohorts at a 7:3 ratio based on their date of admission, resulting in a training cohort of 300 patients and a validation cohort of 128 patients with HER2-positive breast cancer, as well as a training cohort of 170 patients and a validation cohort of 73 patients with TNBC.